What is the 13F Pro Quality Score for GNPX?

13F Pro ranks Genprex, Inc. (GNPX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GNPX's current score at https://13fpro.ai/research/GNPX (free sign-up required for the full ranking).

Where does 13F Pro source GNPX data?

All Genprex, Inc. fundamentals and ownership data come directly from SEC EDGAR. Genprex, Inc. files with the SEC under CIK 1595248. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GNPX in?

Genprex, Inc. (GNPX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GNPX research updated on 13F Pro?

GNPX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Genprex, Inc.(GNPX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1595248 GNPX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

GNPX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Genprex, Inc. (GNPX), a Healthcare sector company. GNPX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Genprex, Inc. reports net income of $-4.5M, free cash flow of $-3.1M. Top institutional holders of GNPX by reported 13-F value include GEODE CAPITAL MANAGEMENT,, MANCHESTER FINANCIAL, Mayflower Financial Advisors,, based on the most recent SEC filings. GNPX trades on the Nasdaq exchange and files with the SEC under CIK 1595248. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GNPX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Genprex, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-4.5M

Free Cash Flow

Q1 2026

$-3.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY21 $0.00FY22 $0.00FY24 $0.00FY25 —

Net Income

+23.1% YoY

$-16.2MFY 2025

FY21 $-20.7MFY22 $-23.7MFY24 $-21.1MFY25 $-16.2M

Operating Income

+26.7% YoY

$-15.5MFY 2025

FY21 $-20.7MFY22 $-23.8MFY24 $-21.2MFY25 $-15.5M

Total Assets

+146.3% YoY

$10.2MFY 2025

FY21 $42.9MFY22 $25.1MFY24 $4.1MFY25 $10.2M

Op. Cash Flow

+14.6% YoY

$-15.3MFY 2025

FY21 $-14.3MFY22 $-17.6MFY24 $-17.9MFY25 $-15.3M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	—	$0.00	$0.00	$0.00	$0.00	—
Net Income	$-16.2M +23.1%	$-21.1M +11.1%	$-23.7M -14.9%	$-20.7M -15.2%	$-17.9M -68.4%	$-10.7M
Operating Income	$-15.5M +26.7%	$-21.2M +11.1%	$-23.8M -15.3%	$-20.7M -15.1%	$-18.0M -68.1%	$-10.7M
Total Assets	$10.2M +146.3%	$4.1M -83.6%	$25.1M -41.5%	$42.9M +36.6%	$31.4M +787.5%	$3.5M
Operating Cash Flow	$-15.3M +14.6%	$-17.9M -1.7%	$-17.6M -23.4%	$-14.3M -2.5%	$-13.9M -101.4%	$-6.9M

AI Insight: GNPX Financial Trends

Pre-revenue biotech burning $3–5M quarterly with equity base recently strengthened to $17M; runway extension unclear without near-term inflection.

• Operating losses stabilized at $3–5M/quarter through Q1 2026; no improvement in burn rate despite 8 quarters of data.

• Equity surged to $17M in Q1 2026 from $1M in Q3 2025, likely via recent financing.

• Operating cash flow improved modestly to negative $3M in Q1 2026 and Q3 2025 from negative $7M in Q2 2024.

⚠ No revenue visible across entire 8-quarter span; clinical or commercialization milestone required to validate funding spend.

⚠ Equity volatility ($1–17M range) signals tight cash position and reliance on successive fundraises to sustain operations.

AI Insight: GNPX Ratio Trends

Genprex remains unprofitable with deeply negative returns; TTM ROE of -98.8% and ROA of -82.4% reflect sustained operating losses.

• ROE deteriorated sharply from -190.4% in Q4 2025 to -105.4% in Q1 2026, indicating smaller quarterly losses but persistent unprofitability.

• ROA worsened from TTM -82.4% to Q1 2026 -87.9%, showing asset base not generating earnings or cash flow.

⚠ No operating margin, NPM, ROIC, or leverage data available; inability to assess profitability drivers or capital structure health.

⚠ Sustained negative ROE and ROA across all visible periods signal core business does not create shareholder value at current scale.

Get alerted when GNPX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Genprex, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GNPX

GEODE CAPITAL MANAGEMENT, LLC
$60.4K33,372 sh
MANCHESTER FINANCIAL INC
$36.2K20,000 sh
Mayflower Financial Advisors, LLC
$36.2K20,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$10.8K5,950 sh
JONES FINANCIAL COMPANIES LLLP
$3.8K2,105 sh
CITIGROUP INC
$3.7K2,039 sh
Cheviot Value Management, LLC
$1.8K1,000 sh
Sound Income Strategies, LLC
$1.6K1,000 sh
OSAIC HOLDINGS, INC.
$417.00232 sh
Bernard Wealth Management Corp.
$362.00200 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$60.4K	33,372
MANCHESTER FINANCIAL INC	$36.2K	20,000
Mayflower Financial Advisors, LLC	$36.2K	20,000
VANGUARD CAPITAL MANAGEMENT LLC	$10.8K	5,950
JONES FINANCIAL COMPANIES LLLP	$3.8K	2,105
CITIGROUP INC	$3.7K	2,039
Cheviot Value Management, LLC	$1.8K	1,000
Sound Income Strategies, LLC	$1.6K	1,000
OSAIC HOLDINGS, INC.	$417.00	232
Bernard Wealth Management Corp.	$362.00	200

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GNPX on your watchlist

Track score changes the day Genprex, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GNPX a good stock to buy?

13F Pro's AI-powered analysis of Genprex, Inc. (GNPX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GNPX are available on the GNPX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GNPX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GNPX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Genprex, Inc.'s investment landscape.